Navigation Links
Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences

- Foundation Purchases Caliper's Staccato System to Enable High Throughput Research Processes -

HOPKINTON, Mass., May 19 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a collaboration with the Peter MacCallum Cancer Centre (PMCC), based in Melbourne, Victoria, Australia. PMCC is using Caliper's Staccato automation system to perform oncology related lab discovery experiments in less time, leading to a better understanding of how to treat and prevent cancer through gene knockdown therapies.

"We would be unable to perform this type of large scale research without the Staccato workstation from Caliper," said Dr. Kaylene Simpson, manager of the Functional Genomics Group at PMCC. "The instrument helps us work towards our primary goals: to identify genes that regulate cancer cell growth, survival, and proliferation, and responses to drug targets."

The Functional Genomics Group at PMCC is funded by the Australian Cancer Research Foundation (ACRF) and provides Australian research institutes with access to large scale, high throughput gene knockdown technology that aids cancer research. By eliminating a gene's ability to express, gene knockdown techniques may uncover ways to silence specific genes associated with cancer, leading to new forms of treatment. Researchers at PMCC are currently working with the Dharmacon entire human and mouse genome collections (~21,000 genes), attempting to knockdown each one. The Staccato enables the researcher to work through these gene sets in a rapid, systematic and reproducible way.

"The Peter MacCallum Cancer Centre's decision to rely on the Staccato reinforces Caliper's position as a leading provider of automation solutions for the life sciences industry," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "Caliper has made significant strides in helping our customers with oncology research. From automation to imaging and tumor models, Caliper provides researchers with the tools to conduct quality oncology research."

Led by Richard Holder, Millennium Science, a distributor of instrumentation and reagents for the biotechnology research and industrial markets, has been a Caliper partner and distributor for 12 years. Millennium worked closely with the PMCC and has been responsible for driving awareness and usage of the Staccato system in Australia.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit

Caliper and Staccato are registered trademarks of Caliper Life Sciences, Inc.

About Peter MacCallum Cancer Centre

In the midst of a worldwide effort, the Peter MacCallum Cancer Centre is in a powerful position to help in the war on cancer. It is one of a handful of comprehensive cancer centres outside the United States and houses the largest cancer research group in Australia, with over 500 staff across the Centre involved in cancer research. The combination of a specialist cancer hospital and an embedded sophisticated laboratory complex provides unparalleled opportunities to inform clinical practice and engage in translational clinical research.

To be most effective, cancer research at Peter Mac has been structured in the form of multidisciplinary teams of laboratory scientists, clinician-researchers and allied health staff. Our spectrum of research ranges from laboratory-based studies into the fundamental mechanisms of cell growth, translational studies that seek more accurate cancer diagnosis, clinical trials with novel treatments, to research aimed at improving our supportive care of patients.

For more information about research at Peter Mac please visit

SOURCE Caliper Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. St. Petersburg: Candlelight Vigil to Raise Awareness of Florida HIV/AIDS Crisis, Honor Lives Lost
2. Shameful Votes Today on Childrens Health Care by Reps. John Peterson, Joe Pitts and Bill Shuster
3. Mayo Clinics Dr. Ronald C. Petersen Awarded Leon Thal Prize for Excellence in Dementia Research
4. Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner
5. Statement from AAJ President Kathleen Flynn Peterson on ATRAs Latest Attack on Civil Justice Attorneys
6. VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer
7. Pennsylvania AFL-CIO Decries Shameful Votes Again by Representatives John Peterson, Joe Pitts and Bill Shuster, Against Childrens Health Care
8. Noted Litigator Peter Diedrich Joins Musick Peeler & Garrett LLP
9. Dr. Peter Covitz Joins MDS Nordion as Senior Vice-President Innovation
10. Leading Cosmetic Dermatologist, Peter G. Ballas II MD, Retains Kay Renz Public Relations to Promote his Practice and New Skincare Line
11. Peter G. Peterson Commits $1 Billion Toward Solving Americas Most Significant Economic Challenges
Post Your Comments:
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology: